MiniMed Group (NASDAQ:MMED) Sets New 12-Month Low – Here’s What Happened

MiniMed Group Inc (NASDAQ:MMED)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $13.52 and last traded at $14.03, with a volume of 44988 shares traded. The stock had previously closed at $14.48.

Key Headlines Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays started coverage with an “overweight” rating and a $26 price target (~80% upside vs. current levels), a clear bullish signal that may drive buying interest. Barclays Overweight, $26 PT
• Positive Sentiment: Bank of America initiated coverage with a Buy rating and a $27 price target, highlighting expectations for pipeline-driven growth after MiniMed’s spin-off — another strong endorsement from a major broker. Bank of America Buy, $27 PT
• Positive Sentiment: Goldman Sachs initiated coverage — high-profile analyst coverage often boosts visibility and can attract institutional flows. Coverage Initiated at The Goldman Sachs Group
• Positive Sentiment: Morgan Stanley began coverage, adding another large sell-side name now tracking MMED which may increase research-driven demand. Morgan Stanley Begins Coverage
• Neutral Sentiment: Evercore initiated coverage; initiation itself raises profile though no publicized rating/target was cited in the item. Coverage Initiated at Evercore
• Neutral Sentiment: Wells Fargo started coverage — added research coverage increases investor access but headline lacked a disclosed PT. Wells Fargo Initiates Coverage
• Neutral Sentiment: Piper Sandler initiated coverage; more broker coverage typically improves trading interest. Piper Sandler Initiates Coverage
• Neutral Sentiment: Deutsche Bank began coverage — another institutional research addition that may increase visibility. Deutsche Bank Begins Coverage
• Neutral Sentiment: Citigroup, BTIG, Mizuho and William Blair also initiated coverage; collectively these add breadth to sell-side coverage but most reports did not publish immediate price targets in the summaries. Citigroup Coverage BTIG Coverage Mizuho Begins Coverage William Blair Coverage

Analyst Ratings Changes

A number of brokerages recently issued reports on MMED. The Goldman Sachs Group assumed coverage on shares of MiniMed Group in a report on Tuesday. They set a “buy” rating and a $24.00 price target on the stock. Barclays began coverage on shares of MiniMed Group in a research report on Wednesday. They issued an “overweight” rating and a $26.00 price objective for the company. William Blair started coverage on MiniMed Group in a research report on Tuesday. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft began coverage on MiniMed Group in a research note on Tuesday. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Sandler initiated coverage on MiniMed Group in a report on Tuesday. They issued a “neutral” rating and a $16.00 price target for the company. Eleven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.45.

MiniMed Group Stock Performance

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.